Cara Therapeutics Announces Participation in ANESTHESIOLOGY® 2017

Tuesday, October 17, 2017 8:01 PM UTC

STAMFORD, Conn., Oct. 17, 2017 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced upcoming CR845 presentations at ANESTHESIOLOGY® 2017, the American Society of Anesthesiologists’ annual meeting, to be held October 21-25, 2017 in Boston.

Presentations will include clinical trial data for CR845, Cara’s first-in-class peripherally selective kappa opioid agonist being developed for the treatment of acute and chronic pain, as well as chronic kidney disease-associated pruritus.

Details for the presentations are as follows:

CR845 Oral Abstract Presentation:

Title:	"Respiratory Effects of I.V. CR845: A Peripherally Acting, Selective Kappa Opioid Receptor Agonist”
Abstract Number:	JS01
Date / Time:	Sunday, October 22, 2017; 9:00 a.m. – 12:00 p.m. ET
Presenter:	Eugene Viscusi, M.D., Director, Acute Pain Management, Thomas Jefferson University

Satellite Symposium:

Title:	"A Potential New Path to Pain Relief: Multimodal Analgesia for Enhanced Recovery with a Peripherally Acting Kappa Opioid Receptor Agonist (KORA)”
Date / Time:	Sunday, October 22, 2017; 7:00 – 8:00 a.m. ET
Presenters:	Joseph Stauffer, D.O., M.B.A., Chief Medical Officer, Cara Therapeutics
	Christopher L. Wu, M.D., Professor, Division of Obstetric Anesthesiology, Division of Regional Anesthesia and Acute Pain Medicine, Department of Anesthesiology, The Johns Hopkins Hospital

For information about ANESTHESIOLOGY® 2017, visit www.asahq.org/annualmeeting.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by CR845, a first-in-class KOR agonist that targets the body's peripheral nervous system. In Phase 2 trials, CR845 has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in patients with moderate-to-severe chronic kidney disease-associated pruritus. Additionally, CR845 has demonstrated initial signs of efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically associated with currently available opioid pain therapeutics.

INVESTOR CONTACT:
Michael Schaffzin
Stern Investor Relations, Inc.
212-362-1200
[email protected]

MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
[email protected]

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Cara Therapeutics Announces Participation in ANESTHESIOLOGY® 2017

Editor's Picks

Welcome to EconoTimes